Sponsored by
This is an experimental gene therapy which I like a lot. Preclinical testing looked very good, and they just completed the phase 1 trial of patients with newly diagnosed high grade glioma. Results will be released next year.
There are a lot of variables to test such as the timing of the components, and perhaps even replacing or eliminating the temozolomide with a different drug for those that won't benefit from it. The temozolomide is a double edged sword. It will kill tumor cells, exposing the insides of the cell to the environment to allow a bigger immune response, but on the other hand temozolomide also kills the immune cells. It is a delicate balance that needs to be tested.